Main industries:

• Medical technology
• Healthcare

TOP 3 markets:

1. USA: approx. 35%
2. Germany: approx. 15%
3. China: approx. 10%

Getinge AB is a leading company in the medical technology industry and generates the majority of its revenue through the sale of products and services in healthcare. The USA is the largest market for Getinge, driven by high demand for advanced medical devices and solutions. Germany and China follow as important markets, with both countries also making significant investments in their healthcare systems.

Production sites of Getinge AB:

Getinge AB produces its products in several countries worldwide. The most important production sites include:

• Sweden: This is where the company's headquarters are located, as well as some of the most significant production facilities, especially for medical technology and hospital equipment.
• Germany: Another central production site, especially for products in the intensive care and surgical workplace areas.
• USA: Getinge also has production facilities in the USA, focusing on the North American market.
• China: In order to better serve the Asian market, the company has also established production capacities in China.

This geographical distribution enables Getinge to efficiently respond to demand in different markets and optimize supply chains.

Revenue Growth: Estimated at 5-7% annually (2025)

Focus on Innovation: Getinge AB is increasingly focusing on the development of new medical technologies and products. This includes particularly the areas of intensive care and cardiovascular technology.

Market Expansion: The company plans to expand its presence in emerging markets such as Asia and Latin America to benefit from the increasing demand for high-quality healthcare solutions.

Sustainability: Getinge places great importance on sustainable practices and has committed to significantly reducing its CO2 emissions by 2030. This is intended not only to reduce environmental impact but also to strengthen the brand image.

These strategic initiatives aim to secure the growth of Getinge AB in the coming years and further expand its market position.

Main raw materials: Stainless steel, plastics, electronic components

Countries of origin:

• Stainless steel: China, Germany
• Plastics: USA, China
• Electronic components: Taiwan, Japan

Getinge AB, a leading provider of medical technology solutions, sources a variety of raw materials and components for the manufacturing of its products. Stainless steel is an essential component for many medical devices and is mainly imported from China and Germany. Plastics used in the production of medical consumables and devices are sourced mainly from the USA and China.

Electronic components, crucial for the advanced functions of the devices, are predominantly sourced from Taiwan and Japan. These countries are known for their high-quality electronic parts that are vital in medical technology.

Market Share: Estimated 10-15% in the field of medical technology (2025)

Research & Development: Investments of approximately 5% of revenue (2024)

Patents: Over 2000 active patents (2024)

Getinge AB has a significant competitive advantage in the field of medical technology, especially through its strong position in the intensive care and infection control segments. The company continuously invests in research and development, leading to a robust pipeline of new products.

Getinge's extensive patent library secures the company a technological edge and protects it from imitators. Additionally, Getinge benefits from a global presence and a broad distribution network that facilitates access to key markets.

Another advantage is the strong brand recognition and trust that Getinge enjoys with its customers, supported by the high quality and reliability of its products.

Institutional Investor Share: approximately 60% (estimated for 2025 based on historical trends)

Insider Purchases/Sales: No specific data available for 2025

The institutional investor share at Getinge AB traditionally stands at around 60%, indicating the trust of large investors in the company. These investors include pension funds, investment companies, and other institutional investors seeking long-term holdings.

There are no specific data available for insider purchases or sales in 2025. Historically, such transactions can be seen as indicators of management's confidence in the company's future development. It is advisable to regularly consult the publications of the Swedish Financial Supervisory Authority or company reports to obtain current information.

Market share of Getinge AB: Estimated 10% (2025)

Top competitors and their market share:

1. Medtronic plc: 15%
2. Johnson & Johnson (MedTech division): 13%
3. Siemens Healthineers: 12%
4. Philips Healthcare: 11%
5. Getinge AB: 10%
6. GE Healthcare: 9%
7. Baxter International: 8%
8. Stryker Corporation: 7%
9. Boston Scientific: 6%
10. Smith & Nephew: 5%

Economic moat of Getinge AB:

Getinge AB has a moderate economic moat, mainly characterized by its specialization in high-quality products in the areas of intensive care and infection control. The company benefits from strong brand recognition and an established distribution network. Additionally, Getinge has invested in research and development in recent years to offer innovative solutions that meet the needs of the healthcare industry.

However, compared to its competitors, Getinge has a less pronounced economic moat than companies like Medtronic or Johnson & Johnson, which have a broader product range and larger financial resources. These competitors can often operate more efficiently due to their size and diversification, exerting a stronger influence on the market.

Overall, Getinge has a solid, but not insurmountable economic moat that can be strengthened through continuous innovation and strategic partnerships.

Revenue Growth: 8% (estimated for 2024)
Profit Growth: 10% (estimated for 2024)
Market Share in Medical Technology: 5% (2023)

Getinge AB has experienced stable revenue and profit growth in recent years. The company benefits from a strong position in the medical technology sector, which is characterized by a growing demand for healthcare solutions.

The strategic focus on innovation and expansion into emerging markets could further support future growth. Additionally, Getinge has been consistently investing in research and development in recent years, which could lead to a competitive advantage in the long term.

Despite challenges in the global supply chain, Getinge demonstrates robust operational efficiency, indicating solid corporate governance. These factors make the stock a potentially attractive investment, especially for investors interested in long-term growth.

Dividend Yield: 2.5% (estimated for 2025)
Dividend History: Continuous payout over the last 5 years

Getinge AB has regularly distributed dividends to its shareholders in recent years. The dividend yield is estimated to be around 2.5% for 2025, based on past payouts and current stock price development.

The company has a solid dividend history and remains consistent in its payout policy. This indicates a reliable dividend payment, although the financial stability and growth potential of the company should continue to be monitored to assess future distributions.